Barriers To Making Acetaminophen Changes Form Basis For Opposition
This article was originally published in The Tan Sheet
Implementing an FDA working group's recommendations to reduce acetaminophen-induced liver injury poses significant challenges that the drug industry could cite in arguing against potential restrictions
You may also be interested in...
Acetaminophen product manufacturers stand to incur huge costs and reduced revenue opportunities if FDA implements a working group's recommendations to reduce hepatotoxicity risk
FDA is considering examining more extensive ways to inform consumers about the dangers of acetaminophen as well as techniques to limit access to OTC drugs containing the analgesic ingredient.
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.